Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry

Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Harrington Investments INC

Financial News Live ·  {{timeTz}}

Harrington Investments INC reduced its position in shares of Hologic, Inc. (NASDAQ:HOLX – Get Rating) by 4.4% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,704 shares of the medical equipment provider's stock after selling 400 shares during the period. Harrington Investments INC's holdings in Hologic were worth $603,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Integrated Advisors Network LLC increased its position in Hologic by 17.1% in the first quarter. Integrated Advisors Network LLC now owns 3,800 shares of the medical equipment provider's stock worth $292,000 after buying an additional 555 shares during the period. Advisor Group Holdings Inc. increased its position in Hologic by 32.4% in the first quarter. Advisor Group Holdings Inc. now owns 38,475 shares of the medical equipment provider's stock worth $2,721,000 after buying an additional 9,410 shares during the period. McGuire Investment Group LLC increased its position in Hologic by 1.2% in the first quarter. McGuire Investment Group LLC now owns 147,777 shares of the medical equipment provider's stock worth $11,352,000 after buying an additional 1,818 shares during the period. Crossmark Global Holdings Inc. increased its position in Hologic by 56.5% in the first quarter. Crossmark Global Holdings Inc. now owns 43,727 shares of the medical equipment provider's stock worth $3,359,000 after buying an additional 15,780 shares during the period. Finally, CIBC Asset Management Inc increased its position in Hologic by 196.3% in the first quarter. CIBC Asset Management Inc now owns 71,148 shares of the medical equipment provider's stock worth $5,466,000 after buying an additional 47,134 shares during the period. 85.70% of the stock is owned by institutional investors and hedge funds.

Get Hologic alerts:

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on HOLX shares. BTIG Research cut Hologic from a "buy" rating to a "neutral" rating in a research note on Monday, July 18th. Bank of America cut Hologic from a "buy" rating to a "neutral" rating and decreased their price target for the stock from $81.00 to $75.00 in a research note on Wednesday, July 20th. Morgan Stanley decreased their price target on Hologic from $72.00 to $70.00 and set an "equal weight" rating for the company in a research note on Thursday, July 28th. Finally, UBS Group started coverage on Hologic in a research note on Wednesday, July 20th. They issued a "neutral" rating and a $73.00 price target for the company. Seven analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, Hologic has a consensus rating of "Hold" and an average target price of $76.71.

Hologic Price Performance

HOLX stock traded up $1.40 during trading hours on Monday, hitting $65.92. 2,996 shares of the stock traded hands, compared to its average volume of 1,760,696. The stock has a 50-day simple moving average of $68.85 and a 200 day simple moving average of $72.05. Hologic, Inc. has a one year low of $61.57 and a one year high of $80.49. The company has a market cap of $16.46 billion, a P/E ratio of 10.88, a P/E/G ratio of 0.73 and a beta of 1.02. The company has a current ratio of 3.91, a quick ratio of 3.32 and a debt-to-equity ratio of 0.57.

Hologic (NASDAQ:HOLX – Get Rating) last announced its earnings results on Wednesday, July 27th. The medical equipment provider reported $0.95 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.26. Hologic had a return on equity of 37.48% and a net margin of 28.93%. The business had revenue of $1 billion during the quarter, compared to analysts' expectations of $896.71 million. During the same quarter last year, the business posted $1.33 earnings per share. The company's quarterly revenue was down 14.2% on a year-over-year basis. Equities analysts forecast that Hologic, Inc. will post 5.82 earnings per share for the current year.

Hologic Profile

(Get Rating)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.

Further Reading

  • Get a free copy of the StockNews.com research report on Hologic (HOLX)
  • Near-Term Headwinds Send Nike To The Bargain Basement
  • Archer Daniels Midland: Dividend Hero With 49 Years Of Increases
  • Will Fully Autonomous Tractors Make Deere the Tesla of Farming?
  • Magna International is Your Auto and EV One-Stop Shop Stock
  • Is the Bond Market Signaling a Market Bottom?

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX – Get Rating).

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites https://www.futuau.com and https://www.moomoo.com/au. Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.